

MARKET REPORT



Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 7, 1, 20, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones). For more information, visit <https://www.bioportfolio.co.uk/product/105846> or email reportstore@bioportfolio.com to order

Kidney Injury) (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9534IDB

Number of Pages : 129

Report Format : PDF

Publisher Information :



Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017 [Report Updated: 11-07-2017]

- Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageAcute Renal Failure (ARF) (Acute Kidney Injury) - OverviewAcute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesAcute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeAcute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics DevelopmentA1M Pharma ABAlloksys Life Sciences BVAm-Pharma BVAngion Biomedica CorpAtox Bio LtdCellmid LtdComplexa IncDiaMedica Therapeutics IncDURECT CorpEvotec AGExponential Biotherapies IncG1 Therapeutics IncKringle Pharma IncMitotech SANephroGenex IncQuark Pharmaceuticals IncRegulus Therapeutics IncSBI Pharmaceuticals Co LtdSpherium Biomed SLSTATegics IncStealth BioTherapeutics IncTorrent Pharmaceuticals LtdXigen SA
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressA1M-001 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAntisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBB-3 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbrimapitide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCAB-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCXA-10 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDM-199 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDrug for Kidney Diseases - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDUR-928 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressEA-230 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progresseslamipretide - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressG-1T100182 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressK-1042 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressK-1052 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressKP-100IT - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMG-53 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNOXD-21 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNYK-1341 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPlastomitin - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPyridoxamine Dihydrochloride - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressQPI-1002 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressR-190 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Human Alkaline Phosphatase - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRecombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressreltecimod sodium - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRLS-003 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRMC-035 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSmall Molecule to Inhibit HDAC for Acute Kidney Injury - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSP-15016 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSTSE-15 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSUL-138 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTRC-160334 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTTX-332 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVanadis-03 - Drug ProfileProduct DescriptionMechanism Of Action
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant ProjectsAcute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued ProductsAcute Renal Failure (ARF) (Acute Kidney Injury) - Product Development MilestonesFeatured News & Press ReleasesJun 12, 2017: A1M Pharma announces progress in the preclinical development of ROSGardMay 22, 2017: AM-Pharma completes patient recruitment of recombinant human Alkaline PhosphataseMar 29, 2017: A1M Pharma: ROSGard shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term studyFeb 10, 2017: A1M Pharma has

successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studiesJan 31, 2017: Angion Biomedica Phase 2 “GUARD” Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft FunctionJan 30, 2017: DURECT Announces Update on DUR-928 Development ProgramDec 20, 2016: Silence Therapeutics Announces Quark Arbitration ResolutionDec 09, 2016: ROSGard shows renal protective effect during radiation therapyNov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injuryMay 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trialApr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney InjuryApr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer

How to Buy...

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017 [Report Updated: 11-07-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/105846>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2000** | Single User Price
- \$4000** | Site License Price
- \$6000** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.